Podcasts about Omics

Are Dire Wolves really back? We give our take on Colossal Biosciences' latest announcement about the de-extinction of Dire Wolves including some thoughts on their approach and some of the broader implications of their work. In other stories, we discuss the early impact of the Trump administration's tariffs on biotech as well as the growing alarm in the scientific community in the wake of sweeping layoffs and leadership departures at the FDA, CDC, and NIH. We also share news from recent scientific conferences and meetings that we've attended as well as an interesting study that used human cell maps to shed new light on pediatric bone cancer.Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching Base.Plex Research Partners with Ginkgo Bioworks to Apply AI-Based Search Engine to Drug DiscoveryBy Uduak Thomas, GEN, April 8, 2025 Danaher-IGI Beacon for CRISPR Cures Celebrates One-Year AnniversaryBy Fay Lin, PhD, GEN, March 28, 2025Human Cell Maps Uncover Insights in Pediatric Bone Cancer By Fay Lin, PhD, GEN, April 10, 2025StockWatch: Biopharma Funds Tumble with Wall Street as Industry Spared from Worst of Tariffs—for NowBy Alex Philippidis, GEN Edge, April 6, 2025 FDA, NIH, CDC Stagger as HHS Axe Falls, Eliminating 10,000 JobsBy Alex Philippidis, GEN Edge, April 1, 2025 Industry Voices Alarm as Peter Marks Departs FDABy Kevin Davies, PhD, and Alex Philippidis, GEN Edge, March 30, 2025The State of Multiomics & NGS 2025Broadcast Date: Wednesday, April 23, 2025 Resurrection Genomics: A Conversation with Colossal's Chief Biology Officer Eriona HysolliThe State of Omics 2024, April 17, 2024 Hosted on Acast. See acast.com/privacy for more information.

Morgan Cheatham joins hosts Raj Manrai and Andy Beam on NEJM AI Grand Rounds to discuss the evolving landscape of artificial intelligence in health care, from its role in automating clinical documentation to its transformative potential in genomic medicine. A venture capitalist and future physician, Morgan shares how his background in computational decision sciences led him to medical school and investing, offering insights into how AI is reshaping everything from disease phenotyping and clinical decision-making to scaling precision medicine. He reflects on his work evaluating ChatGPT's performance on the USMLE, the growing importance of genomic learning health systems, and why the biggest challenge isn't technological innovation—but aligning payment models to support AI-driven advancements in medicine. Transcript.

Osteosarcoma Webinar Series: Sowmya Ramesh, PhD joins us on OsteoBites to discuss how multi-modal omics analysis identifies targetable sensory neuron circuitry that promotes sarcoma disease progression.Bone pain is a hallmark of bone cancers, including osteosarcoma (OS), mediated by skeletal-innervating peripheral afferent neurons. However, the roles of tumor-associated sensory neurons in OS beyond pain perception remain poorly understood. To investigate their regulatory functions, a chemical-genetic approach was employed in mice carrying a knock-in allele for TrkA to perturb sensory nerve innervation during OS growth and progression. TrkA inhibition in these transgenic mice significantly reduced sarcoma-associated sensory innervation and vascularization, altered tumor-associated macrophage polarization, decreased tumor growth and metastasis, and extended overall survival.These findings suggest that targeting pathological innervation in OS may serve as an adjunctive therapy to enhance clinical outcomes and survival.Dr. Ramesh is a postdoctoral researcher from the James lab at Johns Hopkins. The lab's research focus lies at the intersection of skeletal pathophysiology and stem cell biology. The lab looks at the interaction of nerves in various musculoskeletal repair including bone repair and regeneration, osteoprogenitor cell characterization, and neoplastic bone. Dr. Ramesh specifically works on understanding how peripheral nerves regulate osteosarcoma disease progression.

In this insightful episode, I sit down with Andrea Nakayama, a Functional Medicine Nutritionist and educator who has revolutionized how we approach chronic illness. Andrea shares her personal story of resilience after losing her young husband to a brain tumor and how it inspired her to become a leader in Functional Nutrition.We dive into the gaps in Functional Medicine, why chronic illness is at epidemic levels, and Andrea's unique framework for addressing root causes. She explains the pitfalls of overtesting, the importance of bio-individuality, and how to build a therapeutic partnership that empowers clients and practitioners alike. Whether you're navigating your own health journey or supporting others, this conversation is packed with wisdom, practical advice, and inspiration.Key Topics Covered:1.Andrea's Journey: How personal tragedy led Andrea to Functional Nutrition and a mission to transform lives.2.The Chronic Illness Epidemic: Why so many people are underserved by conventional and Functional Medicine approaches.3.Root Cause Methodology: Andrea's systems biology approach and how it addresses the complexity of chronic illness.4.Testing in Functional Medicine: The dangers of overtesting and how to focus on what really matters.5.Personalized Nutrition: How bio-individuality and the science of Omics can guide health transformations.6.Empowering Partnerships: The importance of collaboration between patients, practitioners, and doctors.Memorable Quotes:•“True healing happens when we look beyond symptoms and focus on the whole person.”•“Bio-individuality reminds us that no two health journeys are the same.”•“Chronic illness doesn't have to feel overwhelming when we have the right tools and partnerships.”Connect with Andrea Nakayama:•Website: Functional Nutrition Alliance•Podcast: 15-Minute Matrix•Instagram: @andreanakayamaResources Mentioned in the Episode:•Functional Nutrition Alliance Training Programs•Articles and resources on bio-individuality and root cause healingConnect with Me:•Instagram: @codyjeansanders•Learn more about Mixhers: www.mixhers.comDon't Forget:If you enjoyed this episode, please subscribe, leave a review, and share it with a friend! Your support helps us bring more empowering conversations to your ears.Did you learn something new today? Be sure to subscribe to this podcast and share this episode with all the girls you love. We would appreciate it if you'd also leave us a rating and review on iTunes.Want to join our Mixhers Girl community and keep this conversation going? We'd love to hear your thoughts, feelings and experiences! Join us HERE!Join Mixhers email list and be the first to have access to new products and be the girl in the know!Follow Cody Instagram:@codyjeansanders

ศาสตร์ ‘Omics' เป็นศาสตร์ที่มีบทบาทสำคัญในการทำความเข้าใจกลไกของร่างกายมนุษย์ในภาพรวม โดยไม่ได้มุ่งเน้นเพียงส่วนใดส่วนหนึ่ง แต่ครอบคลุมทั้งระบบร่างกายมนุษย์ เพื่อค้นหาสาเหตุของการเกิดโรคและความผิดปกติทางพันธุกรรมในระดับลึก นำไปสู่การพัฒนาวิธีการรักษาที่มีความแม่นยำและเฉพาะเจาะจงมากขึ้น นอกจากนี้ศาสตร์ Omics ยังเปิดโอกาสทางธุรกิจที่น่าจับตามองในอุตสาหกรรม BioTech โดยเฉพาะในกลุ่มยารักษาโรคมะเร็ง ซึ่งเป็นหนึ่งในผลิตภัณฑ์ที่ใช้งบประมาณวิจัยและพัฒนาสูงที่สุดในบริษัทยาชั้นนำระดับโลก คำถามคือ ประเทศไทยที่โดดเด่นด้านการแพทย์จะคว้าโอกาสนี้อย่างไร Secret Science ชวนพูดคุยกับ ศ. นพ.มานพ พิทักษ์ภากร อาจารย์ประจำสาขาวิชาเวชพันธุศาสตร์ ภาควิชาอายุรศาสตร์ คณะแพทยศาสตร์ศิริราชพยาบาล มหาวิทยาลัยมหิดล ติดตามได้ในเอพิโสดนี้

Jeremy Forman joins us to open up about the hurdles– and successes that come with building data products for pharmaceutical companies. Although he's new to Pfizer, Jeremy has years of experience leading data teams at organizations like Seagen and the Bill and Melinda Gates Foundation. He currently serves in a more specialized role in Pfizer's R&D department, building AI and analytical data products for scientists and researchers. .     Jeremy gave us a good luck at his team makeup, and in particular, how his data product analysts and UX designers work with pharmaceutical scientists and domain experts to build data-driven solutions..  We talked a good deal about how and when UX design plays a role in Pfizer's data products, including a GenAI-based application they recently launched internally.       Highlights/ Skip to: (1:26) Jeremy's background in analytics and transition into working for Pfizer (2:42) Building an effective AI analytics and data team for pharma R&D (5:20) How Pfizer finds data products managers (8:03) Jeremy's philosophy behind building data products and how he adapts it to Pfizer (12:32) The moment Jeremy heard a Pfizer end-user use product management research language and why it mattered (13:55) How Jeremy's technical team members work with UX designers (18:00) The challenges that come with producing data products in the medical field (23:02) How to justify spending the budget on UX design for data products (24:59) The results we've seen having UX design work on AI / GenAI products (25:53) What Jeremy learned at the  Bill & Melinda Gates Foundation with regards to UX and its impact on him now (28:22) Managing the "rough dance" between data science and UX (33:22) Breaking down Jeremy's GenAI application demo from CDIOQ (36:02) What would Jeremy prioritize right now if his team got additional funding (38:48) Advice Jeremy would have given himself 10 years ago (40:46) Where you can find more from Jeremy     Quotes from Today's Episode “We have stream-aligned squads focused on specific areas such as regulatory, safety and quality, or oncology research. That's so we can create functional career pathing and limit context switching and fragmentation. They can become experts in their particular area and build a culture within that small team. It's difficult to build good [pharma] data products. You need to understand the domain you're supporting. You can't take somebody with a financial background and put them in an Omics situation. It just doesn't work. And we have a lot of the scars, and the failures to prove that.” - Jeremy Forman (4:12) “You have to have the product mindset to deliver the value and the promise of AI data analytics. I think small, independent, autonomous, empowered squads with a product leader is the only way that you can iterate fast enough with [pharma data products].” - Jeremy Forman (8:46) “The biggest challenge is when we say data products. It means a lot of different things to a lot of different people, and it's difficult to articulate what a data product is. Is it a view in a database? Is it a table? Is it a query? We're all talking about it in different terms, and nobody's actually delivering data products.” - Jeremy Forman (10:53) “I think when we're talking about [data products] there's some type of data asset that has value to an end-user, versus a report or an algorithm. I think it's even hard for UX people to really understand how to think about an actual data product. I think it's hard for people to conceptualize, how do we do design around that? It's one of the areas I think I've seen the biggest challenges, and I think some of the areas we've learned the most. If you build a data product, it's not accurate, and people are getting results that are incomplete… people will abandon it quickly.” - Jeremy Forman (15:56) “ I think that UX design and AI development or data science work is a magical partnership, but they often don't know how to work with each other. That's been a challenge, but I think investing in that has been critical to us. Even though we've had struggles… I think we've also done a good job of understanding the [user] experience and impact that we want to have. The prototype we shared [at CDIOQ] is driven by user experience and trying to get information in the hands of the research organization to understand some portfolio types of decisions that have been made in the past. And it's been really successful.” - Jeremy Forman (24:59) “If you're having technology conversations with your business users, and you're focused only the technology output, you're just building reports. [After adopting If we're having technology conversations with our business users and only focused on the technology output, we're just building reports. [After we adopted  a human-centered design approach], it was talking [with end-users] about outcomes, value, and adoption. Having that resource transformed the conversation, and I felt like our quality went up. I felt like our output went down, but our impact went up. [End-users] loved the tools, and that wasn't what was happening before… I credit a lot of that to the human-centered design team.” - Jeremy Forman (26:39) “When you're thinking about automation through machine learning or building algorithms for [clinical trial analysis], it becomes a harder dance between data scientists and human-centered design. I think there's a lack of appreciation and understanding of what UX can do. Human-centered design is an empathy-driven understanding of users' experience, their work, their workflow, and the challenges they have. I don't think there's an appreciation of that skill set.” - Jeremy Forman (29:20) “Are people excited about it? Is there value? Are we hearing positive things? Do they want us to continue? That's really how I've been judging success. Is it saving people time, and do they want to continue to use it? They want to continue to invest in it. They want to take their time as end-users, to help with testing, helping to refine it. Those are the indicators. We're not generating revenue, so what does the adoption look like? Are people excited about it? Are they telling friends? Do they want more? When I hear that the ten people [who were initial users] are happy and that they think it should be rolled out to the whole broader audience, I think that's a good sign.” - Jeremy Forman (35:19)   Links Referenced LinkedIn: https://www.linkedin.com/in/jeremy-forman-6b982710/

Dive into the cutting-edge world of cancer research and precision medicine with Dr. Wahid Awad, CEO and Founder of Rosetta Omics. In this episode, we explore how spatial multiomics and AI are revolutionizing cancer treatment. Dr. Awad shares his journey from Egypt to founding a biotech startup in France, and discusses the challenges and opportunities in the field of personalized medicine. Learn about the latest advancements in cancer diagnostics, the role of AI in biotechnology, and how global perspectives are shaping the future of healthcare. Whether you're a science enthusiast, healthcare professional, or simply curious about the future of medicine, this episode offers valuable insights into the forefront of cancer research and biotechnology innovation.   In this episode of Life Science Success, host Don interviews Waheed Awad, CEO and founder of Rosetta Omics. Waheed shares his inspiring journey from Egypt to founding his deep-tech biotech startup in France, focusing on precision medicine and cancer research. Listen in to discover Waheed's innovative use of spatial multiomics and AI, his personal motivation stemming from his father's battle with cancer, and his global experiences shaping his entrepreneurial path. Sponsored by D3 Digital Media Marketing, tune in for an engaging conversation about the future of cancer treatment and personalized medicine.     00:00 Introduction to Life Science Success Podcast 00:40 Sponsor Message: D3 Digital Media Marketing 01:22 Guest Introduction: Waheed Awad 03:06 Waheed's Journey from Egypt to France 08:30 Founding Rosetta Omics 10:10 Personal Connection to Cancer Research 15:25 Global Experiences Shaping Biotechnology 24:06 Rosetta Omics: Precision Medicine and AI 31:16 Balancing Roles and Responsibilities 39:50 Challenges and Inspirations 49:09 Conclusion and Final Thoughts  

BUFFALO, NY- August 21, 2024 – A new #editorial was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science), Volume 16, Issue 15 on August 8, 2024, entitled, “The benefits of exercise on aging: focus on muscle biomarkers.” The focus on maintaining health and vitality (e.g., good healthspan) in later life has become increasingly important as the world's population ages. Over the past few decades, groundbreaking research in the field of aging has deepened our understanding of the molecular basis of this process. In the last decade, advances in aging research have identified biomarkers such as DNA methylation (DNAm) and gene expression, offering insights into both chronological and biological aging. Researchers Robin Grolaux, Bernadette Jones-Freeman, Macsue Jacques, and Nir Eynon from the Australian Regenerative Medicine Institute at Monash University in Melbourne, explore the impact of exercise on these biomarkers in human skeletal muscle—a critical tissue for metabolism, thermogenesis, and movement—revealing its potential to foster healthier aging. This study represents the first quantitative and qualitative analysis of the effects of exercise on age-related biomarkers in human skeletal tissues. Future research could explore the global effects of exercise on various molecular pathways and differentiate between exercise types to develop more effective personalized therapies. “We have the opportunity to uncover functional therapies that effectively impact aging.” DOI - https://doi.org/10.18632/aging.206064 Corresponding Author - Nir Eynon - nir.eynon@monash.edu Video short - https://www.youtube.com/watch?v=Dhiq2I0sW1U Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206064 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, skeletal muscle, exercise, epigenetics, OMICs, biomarkers About Aging-US The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population. The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.) Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Part 3 of 4. My guest for this week's episode is Noam Solomon, CEO and co-founder at Immunai, a pioneering biotech company that is comprehensively mapping and reprogramming the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development, and improve patient outcomes.

Multi-omics is the layering of genetic information (genomics) with laboratory biomarker results (metabolomics) to understand the root cause of disease and risk. This educational series focuses on genetic variants in specific enzymes and explains how to evaluate the systemic effects. Today's episode revolves around the enzyme cystathionine-beta-synthase (CBS). This enzyme is important for homocysteine metabolism, sitting at a branch point between two important cycles: methylation and transsulfuration. The action of this enzyme is important for balancing the critical functions of methylation with the creation of glutathione and energy. Listen to understand why this enzyme is important and what a genetic variant in CBS might mean for you and your patients. Today on The Lab Report: 2:20 Reminder of what we mean by multi-omics 4:50 Introducing the CBS enzyme and the sink drain metaphor 7:40 The genetics of CBS – the silent mutation – and its potential effects 12:40 Better Know A Biomarker:  Cystathionine! 16:20 Activators and inhibitors of CBS and its effects on other biomarkers 18:55 Question of the Day:  Does a CBS SNP cause elevated ammonia levels? 21:40 Evaluating surrounding biomarkers and how do you treat this SNP? Additional Resources: Methylation Panel Genova Connect **PROMO CODE TheLabReport20 for 20% off your purchase**   Subscribe, Rate, & Review The Lab Report Thanks for tuning in to this week's episode of The Lab Report, presented by Genova Diagnostics, with your hosts Michael Chapman and Patti Devers. If you enjoyed this episode, please hit the subscribe button and give us a rating or leave a review. Don't forget to visit our website, like us on Facebook, follow us on Twitter, Instagram, and LinkedIn. Email Patti and Michael with your most interesting and pressing questions on functional medicine: podcast@gdx.net. And, be sure to share your favorite Lab Report episodes with your friends and colleagues on social media to help others learn more about Genova and all things related to functional medicine and specialty lab testing. To find a qualified healthcare provider to connect you with Genova testing, or to access select products directly yourself, visit Genova Connect. Disclaimer: The content and information shared in The Lab Report is for educational purposes only and show not be taken as medical advice. The views and opinions expressed in The Lab Report represent the opinions and views of Michael Chapman and Patti Devers and their guests.See omnystudio.com/listener for privacy information.

What's the buzz in omics all about and how can it help you make better beer? Special Guests: Glen Fox, Harmonie Bettenhausen, and Laura Burns.

Guang Li, PhD, researcher at UPMC Children's Hospital of Pittsburgh discusses his research on the developing heart with the hope of one day preventing congenital heart defects.

Have you ever wondered if there was a way to gain deep insights into your body's unique needs and optimize your health? The answer may lie in the cutting-edge field of metabolomics.   In today's episode of the Longevity Podcast, Dr. Paniz Jasbi, the co-founder of Theriome, and I discuss how their groundbreaking Aristotle test is revolutionizing the way we approach health and wellness. From assessing mitochondrial function and nutritional status to identifying potential disease risks and guiding personalized interventions, the Aristotle test is a game-changer for precision medicine. Overall, we discuss this test's ability to offer valuable insights for dealing with complex health issues, recovering from illness, or optimizing your athletic performance.   Dr. Paniz Jasbi founded Theriome in 2022. Integrating the theory of –omics sciences, Theriome seeks to innovate personalized wellness by analyzing the totality of systems biology—from the genome to the metabolome, and everything in between.   Use code NAT to save when ordering the Theriome metabolomic test for 10% off. Shop here: https://therio.me/      Thank you to our sponsors for making this episode possible: Vitali: Visit https://www.vitaliskincare.com/discount/Nathalie20 and use code Nathalie20 to save on your order. Mitopure: Use code NAT10 for 10% off your order at https://www.timelinenutrition.com/shop/nutrition Berkeley Life: Consumers may register and place an order using my code NIDDBL for 10% off at berkeleylife.com   Find more from Dr. Paniz Jasbi:  Website: https://therio.me/    Instagram: @theriometest   Book: Theriome and the Aristotle Test   Find more from Nathalie: YouTube: https://www.youtube.com/channel/UCmholC48MqRC50UffIZOMOQ  Join Nat's Membership Community: https://www.natniddam.com/bsp-community  Sign up for Nats Newsletter: https://landing.mailerlite.com/webforms/landing/i7d5m0  Instagram: https://www.instagram.com/nathalieniddam/  Website: www.NatNiddam.com    Facebook Group: https://www.facebook.com/groups/biohackingsuperhumanperformance  What We Discuss:  04:30 Understanding the Omics 09:58 Leveraging AI in Metabolomics 19:25 The Microbiome and ILIA Test 23:35 Exploring Spermidine and Other Metabolites 45:41 The Importance of Directly Assessing Mitochondrial Function 50:08 The Implications of Disease Enrichment Analysis 52:56 The Importance of Access to Personal Health Information 01:07:24 The Accessibility and Affordability of the Test  

BUFFALO, NY- July 9, 2024 – A new #editorial paper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 12, entitled, “Aging retinal pigmented epithelium: omics-based insights into vision decline.” In this new editorial, researchers Ioan V. Matei and Luminita Paraoan from Edge Hill University discuss vision decline with aging. Of all senses affected by aging, vision decline arguably has the most impactful relationship with overall wellbeing, health and personal autonomy. However, while the ensuing importance of vision loss has long been recognised from a public health perspective given an increasingly aging population, understanding the molecular and cellular mechanisms driving age-related pathological changes is still in its infancy. “This matter is, therefore, critical for tackling sensory impairment and ensuring healthy aging.” The retinal pigmented epithelium (RPE), the cellular monolayer located between the neuroretina and the highly vascularized choroid, from which it is separated by Bruch's membrane (BrM), has a critical role in human vision and performs essential functions throughout life for maintaining the retinal homeostasis. RPE is a specialised, fully differentiated tissue that is mitotically inactive, with no regenerative potential. Unsurprisingly, given all its characteristics, functions and metabolic demands, the RPE is particularly susceptible to aging, sustaining significant morphologic and physiologic changes. “Aging is recognised as the highest risk factor for age-related macular degeneration (AMD), the leading cause of adult visual impairment and blindness in the Northern Hemisphere, which is directly linked to specific pathological changes of the RPE located in the macula, i.e., the central part of retina; these changes, therefore, affect central vision required for reading, driving, and discerning details of pictures, faces, shapes and colors.” DOI - https://doi.org/10.18632/aging.205914 Corresponding author - Luminita Paraoan - Luminita.Paraoan@edgehill.ac.uk Video short - https://www.youtube.com/watch?v=_-zhhFjlQ4Y Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.205914 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, RPE, vision, omics About Aging-US The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population. The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.) Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

In this episode of AI For Pharma Growth, Dr. Andree Bates is joined by Abishek Jha, Co-Founder and CEO of Elucidata, which cleans and links biomedical data at scale. They advocate for a data-centric approach to AI, arguing that clean data is more valuable than copious data.   In this episode, you will learn: How Elucidata's sources and processes data The problems they solve for biopharma companies How they're structuring biological data with their biomedical data platform, Polly   For more information on Abishek Jha's work with Elucidata, head to https://www.elucidata.io/    Click to connect with Dr. Andree Bates for more information in this episode: https://eularis.com/   AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr. Andree Bates created to help organisations understand how the use of AI based technologies can easily save them time and grow their brands and business.  This show blends deep experience in the sector with demystifying AI for all pharma people, from start up biotech right through to Big Pharma. In this podcast Dr Andree will teach you the tried and true secrets to building a pharma company using AI that anyone can use, at any budget. As the author of many peer-reviewed journals and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses  her obsession with all things AI and futuretech to help you to navigate through the, sometimes confusing but, magical world of AI powered tools to grow pharma businesses.  This podcast features many experts who have developed powerful AI powered tools that are the secret behind some time saving and supercharged revenue generating business results. Those who share their stories and expertise show how AI can be applied to sales, marketing, production, social media, psychology, customer insights and so much more.   Resources: Dr. Andree Bates LinkedIn | Facebook | Twitter

Episode 17 (April 12, 2024): This week, the GEN editors discuss the launch of Nvelop Therapeutics, a new start-up leveraging approaches developed by gene editing pioneers David Liu, PhD, and J. Keith Joung, MD, PhD, to advance delivery of genetic cargo. The GEN editors also recap highlights from the American Association for Cancer Research (AACR) annual meeting held in San Diego, California. Featuring Uduak Thomas (Senior Editor, GEN), Alex Philippidis (Senior Business Editor, GEN), Julianna LeMieux, PhD (Deputy Editor-in-Chief, GEN), and Jonathan Grinstein, PhD (Senior Editor, GEN), and moderated by Fay Lin, PhD (Senior Editor, GEN Biotechnology) Listed below are key references to the GEN stories, media, and other items discussed in this episode of Touching Base: The State of Omics 2024 Registration GEN Summit Cloaking Device: Liu, Joung Launch $100M Nvelop Therapeutics to Advance Delivery of Genetic Cargo By Alex Philippidis, GEN Edge, April 9, 2024 Bertozzi, Regev, and More Inspire During the Opening Plenary Session of AACR By Julianna LeMieux, PhD, GEN, April 8, 2024 AACR 2024: Aviv Regev Shows How Single-Cell Atlases Foster New Axis to Genentech's Drug Discovery By Jonathan Grinstein, PhD, GEN, April 8, 2024 AACR 2024: A Video Update from San Diego By Julianna LeMieux, PhD, and Jonathan Grinstein, PhD, GEN, April 8, 2024 A Video Update from Day Two of the AACR Meeting By Julianna LeMieux, PhD, and Jonathan Grinstein, PhD, GEN, April 9, 2024 AACR 2024: EpiBiologics Advances Degraders of Membrane-Bound Proteins By Jonathan Grinstein, PhD, GEN, April 8, 2024 Celebrating National Robotics WeekBy Uduak Thomas, GEN, April 12, 2024 Hosted on Acast. See acast.com/privacy for more information.

Episode 16 (April 5, 2024): This week, the GEN editors discussed deep proteome profiling of home-sampled dried blood spots to assess the effects of SARS-CoV-2 in mildly symptomatic or asymptomatic, rapid liquid nitrogen treatment for converting tumor cells into carriers for gene editing tools that target cancer in vivo, Verve Therapeutics' pausing of a clinical trial due to a serious adverse event, Iambic Therapeutics' advancement of its first AI-designed candidate into the clinic, and the launch of Diagonal Therapeutics to find agonist antibodies for heteromeric receptor complexes. Featuring Uduak Thomas (Senior Editor, GEN), Alex Philippidis (Senior Business Editor, GEN), Jonathan Grinstein, PhD, (Senior Editor, GEN), and moderated by Corinna Singleman, PhD, (Managing Editor, GEN and IPM) Listed below are key references to the GEN stories, media, and other items discussed in this episode of Touching Base: The State of Omics 2024 Registration GEN Summit COVID-19 Infections Detected in Dried Blood Spots via At-Home Proteomic ProfilingBy GEN, April 2, 2024. CRISPR-Cas9 Targets Lung Cancer Using Cryo-Shocked Tumor CellsBy GEN, March 31, 2024. Iambic Rhythm: AI Drug Developer Enters the Clinic, Targeting HER2 CancersBy Alex Philipidis, GEN, April 3, 2024. Archimedes' Box: Diagonal Therapeutics Raises $128 Million to Discover Agonist AntibodiesBy Jonathan D. Grinstein, PhD, GEN Edge, April 3, 2024. Hosted on Acast. See acast.com/privacy for more information.

Dr. Chaps interviews Dave Bratt, an economist who has the solution to our upside-down economy, and you will be surprised to learn what it is. Ever wonder how we can sustain a $30 trillion debt? In this interview, we learn that, in the long run, we can't, unless we make a major change. You will not want to miss key insights about the future of America's economy in this important interview. Get free alerts at http://PrayInJesusName.org © 2024, Chaplain Gordon James Klingenschmitt, PhD. Airs on NRB TV, Direct TV Ch.378, Roku, AppleTV, Amazon FireTV, AndroidTV, GoogleTV, Smart TV, iTunes and www.PrayInJesusName.org

For this year's SLAS2024 conference in Boston (which takes place 3-7 February), DDW's Megan Thomas narrates articles from the DDW SLAS2024 supplement as part of the DDW Events podcast series. This is episode five, Solving the diagnostic odyssey with multi-omics. Catherine Brownstein is an Assistant Professor in Pediatrics at Harvard Medical School and the Assistant Director of the Molecular Genetics Core Facility at Boston Children's Hospital. Her current work focuses on advancing the fields of genome sequencing and analysis, with an emphasis on identifying complex structural variation. She spoke with me on how genomics can advance drug discovery and development.

After realizing at a young age that rock and roll might be a better hobby than a career, our guest chose chemistry and chromatography as his path, and he's rocked that career choice!In this fun and engaging conversation, you'll meet Frank Steiner, PhD, Senior Manager of Product Applications, and Scientific Advisor at Thermo Fisher Scientific, who has earned much respect for his contributions to the field of high-performance liquid chromatography (HPLC). He and his team are customer number one for new HPLC products and generate much of the data used to support product launches. Steeped in the theory and fundamentals of HPLC, they provide us with a very approachable summary of the technique and considerations that must be balanced across diverse applications. Follow Frank and Paolo as they uncover insights on the evolutionary arc of HPLC, what challenges still exist, and why Frank believes it to be the technique that is most widespread and effective in affecting our lives. As always, we promise to let you get to know Frank, his personal story, and some bits of sage advice from a man that's been there and done that. Related episodes: Season 1, Ep.3: There's chemistry is in the air!Season 1, Ep.7: Stronger magnets, stronger scienceSeason 4, Ep.7: From an F in chemistry to 40 years in chemicals Bonus content!Access bonus content curated by this episode's guest by visiting www.thermofisher.com/chemistry-podcast for links to recent publications, podcasts, books, videos and more.View the video version of this episode on www.thermofisher.com/chemistry-podcast. A free thank you gift for our listeners! Visit the episode website and request your free Bringing Chemistry to Life t shirtUse Podcast Code:  2023wrap in December 2023 or Ba++ery in January 2024 Share your feedback with us! Email helloBCTL@thermofisher.com About Your HostPaolo Braiuca grew up in the North-East of Italy and holds a PhD in Pharmaceutical Sciences from nearby esteemed University of Trieste, Italy. He developed expertise in biocatalysis during his years of post-doctoral research in Italy and the UK, where he co-founded a startup company. With this new venture, Paolo's career shifted from R&D to business development, taking on roles in commercial, product management, and marketing. He has worked in the specialty chemicals, biotechnology, and pharmaceutical markets in Germany and the UK, where he presently resides. He is currently the Director of Global Market Development in the Laboratory Chemicals Division at Thermo Fisher Scientific™ which put him in the host chair of the Bringing Chemistry to Life podcast. A busy father of four, in what little free time he has, you'll find him inventing electronic devices with the help of his loyal 3D-printer and soldering iron. And if you ask him, he'll call himself a “maker” at heart.

Earl ends the show discussing the state of the economy in the United States. He talks about the price of gas, the rate of inflation, the recovery from the pandemic, and the measures take to address crumbling infrastructure. The Earl Ingram Show is a part of the Civic Media radio network and airs Monday through Friday from 8-10 am across the state. Subscribed to the podcast to be sure not to miss out on a single episode! To learn more about the show and all of the programming across the Civic Media network, head over to https://civicmedia.us/shows to see the entire broadcast line up. Follow the show on Facebook and X to keep up with Earl and the show!

Commentary by Dr. Valentin Fuster

Gene and Alyssa answer tons of listener questions: Is this grandma helping her 5 grandchildren with college costs (food) getting in trouble with the IRS? She wants to know when she must take withdrawals and from which accounts? Can you use the cash value from a life insurance contract to fund an annuity? They are retiring at ages 69 and 66. What do they do with their 401(k)s? Lots more . . . Free Second Opinion Meetings Do you have questions about your financial situation? Are you on track to reach your financial goals – particularly your retirement goals? What should you be doing right now? Are you taking too much risk with your investments? Is your 401(k) or 403(b) being actively managed for you? Schedule a free second opinion meeting with a More than Money advisor? Call today (610-746-7007) or email (Gene@AskMtM.com) to schedule your time with us.

Root cause medicine is all the rage if you follow any functional medicine experts and while that is an important part of treating you as a whole, root causes are not the only thing we need to think about.  My guest on this episode, functional nutritionist Andrea Nakayama, so beautifully talks about the roots but also the branches, the various systems and terrains of our body and lifestyles. She also shares the developing science of omics, the reason some of us react differently to foods, medicines, supplements, viruses, etc. than someone else. Andrea also shares much of her journey with her own health as well as the loss of her husband and how her experiences with autoimmunity and her husband's cancer have shaped the way she sees functional medicine and health.    Learn more about Andrea's work here.    To work with Dr Brooke click here and if you loved this episode please leave a review!     Follow Dr Brooke on Instagram and get signed up for my awesome emails here. Seriously,I write really great emails, or so 1000s of women tell me and I'd like to send you one too.   Be sure you connect with me in my FREE PRIVATE Facebook group: Hormones & Happiness with Dr Brooke where other amazing, like minded women like YOU are already hanging out! Join us! Partners of the Dr. Brooke Show (Stuff I Know You Will Love!)   This episode is also sponsored by Organifi whose green juice is my absolute favorite on the market. It's certified USDA organic, contains 11 superfoods including the heavy hitters spirulina and matcha, includes 600mg of ashwaganda and is a great boost of antioxidants for better energy, less brain fog and better exercise recovery. And ladies, you're going to want to try Harmony! Their female hormone balancing blend of shatavari, maca and vitex in a delicious cacao base. Save 20% with code BETTEREVERYDAY at checkout.  Aging is a part of life, but our cells don't always complete their normal life cycle so well due to a host of factors in our modern world. When cells don't go through a healthy life cycle process they become what are called “zombie cells” - nonfunctional and unhelpful but still sucking up resources from the healthy cells around them. This process of senolysis can be aided by key ingredients found in Neurohacker's amazing product: Qualia Senolytic. Clear out those dead cells and see your brain, skin and body come back alive. Save 50% off with this link and use code BETTEREVERYDAY at checkout for an additional 15% off! This is anti-aging at its core and you only need to take this a couple days of the month! And there is a money back guarantee, get yours here.

 In this episode, the hosts have an intriguing discussion with Dr. Ben Sun, Head of Biomarker Genetics at Biogen.  Dr. Sun holds an MD/PhD from the University of Cambridge, providing a view and perspective on data from both research and clinical perspectives. The advantage of his unique background is that it provides a balanced perspective on large-scale population data and genomic data sets used to train computational models for predicting and informing clinical treatment.  The conversation touches on the fundamental science as well as the integration of in silico, in vitro, and in vivo methods. Ben also shares insights on decision-making is different in research vs. clinical spaces and on the types of variations that can make it challenging to train and confidently use AI in healthcare.  Subscribe to be notified when future episodes drop. For full access to the video and transcripts, please visit our Thermofisher page directly at https://www.thermofisher.com/us/en/home/global/forms/life-science/subscribe-speaking-mol-bio-podcast.html  In the meantime, we hope you'll share our podcast with a friend or colleague that might enjoy it. And as you progress in your own work, we hope you'll visit the Invitrogen School of Molecular Biology (https://thermofisher.com/ISMB) where you can access molecular biology resources to help you achieve your goals. 

This month, Surfing NASH embarks on a series of episodes dedicated to takeaways emerging from June's two major conferences: the 2023 EASL Congress in Vienna and the American Diabetes Association's 83rd Scientific Sessions meeting in San Diego. In doing so, the Big Band of Surfers (Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green) are joined by Mazen Noureddin for a fascinating conversation which covers compelling data and ideas emerging from the drug development space.Mazen starts this conversation by stressing the importance of omics, particularly metabolomics and proteomics, in creating a single blood-based measure that can offer standardization around evaluation or, otherwise, a small set of standard tests. He goes on to describe breakthrough obesity presentations at the ADA meeting and returns to the question that he raised in Episode 31: do we need NASH drugs given how powerful the upcoming weight-loss pharmacotherapies will be? He simply says, yes we do, and describes why. Stephen returns to the topic of omics, stating his preference for additional omics works, albeit with some skepticism about proteomics. That said, he questions whether omics will get a far enough and expresses hope that epigenetics might get even further. The rest of this conversation entails Mazen, Stephen and Jörn discussing biomarkers and omics issues. Stephen wraps up the session by noting that we will have plenty to talk about in this arena for years to come. Finally, he mentions AI as another key area for future growth. Each conversation covers a lot of ground on drug development, analysis of trial results, and the upcoming increases in importance of omics and artificial intelligence. If you have questions or comments around the EASL Congress or ADA meetings, or the themes and data discussed in this episode, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.Stay Safe and Surf On

Dr. Stan Roux, Professor of Molecular Biosciences at the University of Texas – Austin, has had a long and successful career based on his fascination with plants and his desire to understand plant biology. He's spent his career exploring the effect of apyrase on root systems, crop yields, and plant nutrient uptake. We get into Stan's unlikely career path and how a chance conversation with a colleague at a conference led to his 25 years of collaboration with NASA and experiments on space missions to help understand the effect of gravity on plant development that could inform how plants are cultivated on the moon or Mars. Join us for this fascinating discussion on the impact of transcriptomics and proteomics in research and the mysteries of plants that are yet to be solved. Tune in today. Subscribe to get future episodes. Share with a friend or colleague that might enjoy too! Visit https://thermofisher.com/ISMB to access molecular biology resources and educational content. Experience the Speaking of Mol Bio podcast in its extended video format for a more immersive journey, while also ensuring accessibility with downloadable transcripts for each episode. Watch now at thermofisher.com/podcast-video

President Biden gave a major speech on the economy today, laying out “Bidenomics” as he tries to convince Americans to let him handle the economy for 4 more years. We'll break down what it means for your money and the markets. Plus, Tesla shares have more than doubled this year, and analysts are starting to say it's gone too far, too fast. We'll talk to Toni Sacconaghi, whose price target is more than $100 per share below Tesla's current price.

In this podcast, we interview Dr. Jonas Schluter, Assistant Professor from the Department of Microbiology at the Grossman School of Medicine at NYU Langone Health and a winner of the DNA Genotek and Diversigen 2021 Expand into Multi-omics grant, discuss his research.

Dr. Bajnath is a Board-Certified Family Physician and author of The Longevity Equation: The Step-By-Step Blueprint to Hack Your Genes, Optimize Your Health, And Master the Art of Existence. His approach to medicine incorporates precision personalized healthcare modalities such as individualized nutrition, genomic medicine, advanced biomarker testing, microbiome analysis, and biometric lifestyle monitoring. In today's conversation we'll be exploring what omics are and how Dr. Bajnath uses precision medicine to create personalized treatment plans for his patients. We'll also talk about how he integrates this approach into his medical practice and what you can do to bring this level of care into your wellness plan. So, if you're curious about precision medicine and how it can improve your health, you definitely don't want to miss this episode.

Multi-omics is a great example of how the scientific community is thinking larger and using complementary methods to gather deeper information to understand biology and inform medicine.  Proteomics is just one of the -omes of multi-omics but it's the one that Steve Williams, Chief Medical Officer at SomaLogic, has over 30 years' experience in. Steve joins us to share his story and insights on how protein biology complements genetic profiling to enable measurement of thousands of biomarkers to produce personalized data that has the potential to change the way diseases are identified and treated. Join us to meet this interesting man and how he believes multi-omics can serve as the search engine to human biology. We hope you'll listen today and subscribe to get notification of future episodes as they drop. If you enjoy the show, we hope you'll share it with a friend or colleague that might enjoy it too! Visit https://thermofisher.com/molbioschool to access molecular biology resources and educational content. Experience the Speaking of Mol Bio podcast in its extended video format for a more immersive journey, while also ensuring accessibility with downloadable transcripts for each episode.Watch now at thermofisher.com/podcast-video

Guang Li, PhD, researcher at UPMC Children's Hospital of Pittsburgh discusses his research on the developing heart with the hope of one day preventing congenital heart defects.    

In this month's episode of the American Blue Economy Podcast, host Rear Admiral Tim Gallaudet, PhD, US Navy (ret) explores the many benefits of biotechnology to the American Blue Economy, Drawing from his recent article in Real Clear Science, 7 Technologies Revolutionizing Our Understanding of the Ocean | RealClearScience, he is assisted by 4 of his former colleagues from the National Oceanic and Atmospheric Administration (NOAA). These exceptional experts include: Dr. Kelly Goodwin, ‘Omics lead for NOAA's Office of Oceanic and Atmospheric Research; Dr. Luke Thompson, Associate Research Professor with NOAA's Northern Gulf Institute at Mississippi State University and NOAA's Atlantic Oceanographic and Meteorologic Laboratory; Dr. Jeanette Davis, a Marine Microbiologist, bestselling author, and Policy Advisor to the Deputy Undersecretary at NOAA; and Dr. Krista Nichols, Genetics and Evolution Program Manager at NOAA's Northwest Fisheries Science Center and NOAA's Omics Working Group Vice Chair. Be ready to be marveled by the magnificent field of marine microbiology in the American Blue Economy!

In this episode, we talk with Chris Whelan about the data behind science.  Chris is the Director of Neuroscience, Data Science & Digital Health for Research and Development at The Janssen Pharmaceutical Companies of Johnson & Johnson, as well as the Chair of the UK Biobank Pharma Proteomics project. He connects the dots between genomics and proteomics and clarifies how omics can be used to understand disease biology to inform drug development to treat disease. The conversation touches on the challenges of defining and collecting a comprehensive biomarker panel, and he also delves into the role of data science and the importance of having people that understand biology being involved in data science applications that affect human health.   If you enjoy this great conversation with a leader in his field we hope you'll subscribe to the series to get future episodes as they drop.  Visit https://thermofisher.com/molbioschool to access molecular biology resources and educational content. Experience the Speaking of Mol Bio podcast in its extended video format for a more immersive journey, while also ensuring accessibility with downloadable transcripts for each episode.Watch now at thermofisher.com/podcast-video

The in-depth approach shows mutations in the autism-linked gene disrupt neuronal growth and communication, as well as mitochondrial gene expression. The post Multi-omics study captures CNTNAP2's far-ranging effects appeared first on Spectrum | Autism Research News.

Evaluating single cell omics to understand the heterogeneity in immune and tumor cellsMulti-omic biomarkers for patient selection in solid tumor IO: is there a path to more personalized therapy?In an era of ‘targeted' therapies against cell-intrinsic mechanisms (e.g. PARP, NTRK, BRAF) and surface molecules (Nectin-4, HER2), is there a path forward for pan-tumor biomarkers, or is multi-tumor more likely to be the dominant development mechanism? Moderated by: Theresa LaVallee, PhD, VP, Translational Medicine and Regulatory Affairs, Parker Institute for Cancer Immunotherapy Panelists: Jared Lunceford, PhD, Distinguished Scientist, Biostatistics and Research Decision Sciences, Merck Research LaboratoriesAngel A Rodriguez, MD, Oncology Medical Director, NateraSamik Upadhaya, PhD, Research Analyst, Anna-Maria Kellen Clinical Accelerator and Venture Fund, Cancer Research Institute (CRI) Learn more about the IO360° Summit at www.io360summit.com

The in-depth approach shows mutations in the autism-linked gene disrupt neuronal growth and communication, as well as mitochondrial gene expression.

The in-depth approach shows mutations in the autism-linked gene disrupt neuronal growth and communication, as well as mitochondrial gene expression.

Host Stan Gloss, founder of BioTeam, talks with Aaron Friedman, HealthAI Principal Product Manager at Amazon Web Services, about the launch of Amazon Omics. This new purpose-built service helps healthcare and life science organizations store, query, and analyze genomic, transcriptomic, and other omics data to generate insights that improve health and advance scientific discoveries. The platform simplifies and accelerates the process of storing and analyzing data for research and clinical applications. On the day of the announcement, Friedman discusses why Amazon Omics will best suit small and large biotech companies and make it easier for various organizations to mine their data. He also outlines its key features, how it combines data with other modalities, and why it lends itself to top-tier multi-omics and multimodal analysis. Links from this episode:  Bio-IT World BioTeam Amazon Web Services AWS Omics Trends from the Trenches boiler: Bio-IT World's Trends from the Trenches podcast delivers your insider's look at the science, technology, and executive trends driving the life sciences through conversations with industry leaders. BioTeam co-founder Stan Gloss brings years of industry experience in science, data, and technology to conversations exploring what is driving data and discovery, and what's coming next.

David Brady, ND, DC, CCN, DACBN, IFMCP, FACN, joins Integrative Practitioner associate editor, Avery St. Onge, to discuss the gut-brain connection and how to apply a multi-omics approach to treat stress, anxiety, and depression. This episode is brought to you in part by the Integrative Healthcare Symposium. Find us at integrativepractitioner.com or e-mail us at IPEditor@divcom.com. Theme music: “Upbeat Party” by Scott Holmes via freemusicarchive.org and “Carefree” by Kevin Mcleod via incompetech.com.

In a follow-up preview, Jörn Schattenberg, Louise Campbell, Mazen Noureddin, Ian Rowe and patient advocate Jeff McIntyre join Roger Green to discuss key presentations and posters of interest at the 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). On November 4th-8th in Washington DC, as many as 10,000 attendees will convene in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care.Jörn starts this conversation by noting his anticipation for Parallel 12: NASH therapeutics and OMICs. Specifically, he points to an abstract titled Novel Mobile Health Delivered Lifestyle Intervention Program (Noom Health Weight) in Patients with NASH: a randomized controlled proof of concept study. This is a small trial in patients with NASH and obesity. The study sought to measure weight loss alongside weekly engagement with the Noom Healthy Weight app. 70% of patients met the engagement goal and lost an average of 5.3 kg over 16 weeks. Patients undergoing a more typical lifestyle management lost an average of 1 kg. Jeff joins to highlight the potential of a remote technology to generate 70% weekly engagement. He also finds this data promising in terms of providing a program that patients can use to measure health and manage fatty liver disease. By contrast, Jeff discusses recent conversations with a patient recently diagnosed with NAFLD who was not maintaining successful self-management due to obscurity of direction. Roger cautions that while this trial reported “no adverse event,” it consisted of a small sample size and short study duration. He also raises questions around the commercial model buttressing this study: who is paying and for how long can they maintain motivation? He envisions a more viable approach will be supported by commercial payers, who in return are investing in health care data. Given this may take some time to play out, Roger casts a third suggestion: FDA-approved digital therapeutic apps. He predicts this to be fertile grounds for patient empowerment over the next few years.As this session winds down, Jeff responds to several of Roger's comments and notes the turbulent impact of a pandemic on participation in wellness apps. This topic extends into the next conversation.

In a follow-up preview, Jörn Schattenberg, Louise Campbell, Mazen Noureddin, Ian Rowe and patient advocate Jeff McIntyre join Roger Green to discuss key presentations and posters of interest at the 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). On November 4th-8th in Washington DC, as many as 10,000 attendees will convene in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care.Mazen begins by highlighting a presentation by Laurent Castera which covers an abstract the two collaborated on. The paper looks to validate and compare head-to-head the FASTTM, MAST, and MEFIB scores as well as FIB-4 and NAFLD fibrosis score in a large cohort of T2D patients with NAFLD. Roger notes last week's discussion on use of FIB-4 as a primary screening tool, commending its performance in NPV but not PPV. He suggests this study offers a way forward for an enriched population who would benefit from a test offering high PPV and a narrow indeterminate zone. Jörn and Louise respond with their thoughts on FIB-4 as a cheap, accessible tool for primary care. Their analysis aligns with a conclusion from last week's preview: FIB-4 is not a tool for the specialist's office but, instead for primary care practices conducting first-line screening.Ian suggests some of the preceding conversation anchors performance of these tests to biopsy. Interested in moving beyond biopsy, he points out presentations which compare outcomes of patients according to either biopsy or associated noninvasive tests. The first paper investigates whether screening for advanced fibrosis in the community can identify the subgroup of people with NAFLD at higher risk for development of liver-related complications. The study aimed to determine the prognostic value of baseline noninvasive fibrosis tests for predicting liver-related outcomes and mortality in patients with NAFLD from T2D clinics or primary care. Ian then looks at a presentation by Samer Gawrieh which provides data on progression. Mazen agrees with the idea that as data accumulates around NITs, we can better understand how longitudinal changes impact outcomes.Jörn highlights his anticipation for Parallel 12: NASH therapeutics and OMICs. He specifically points to a presentation by Jonathan Stine on answering an unmet need to develop effective lifestyle intervention programs. This randomized proof of concept trial evaluates the feasibility, acceptability and safety of a novel commercially available mobile health app. This topic immediately resonates with Jeff, who is encouraged by two elements: the development of remote personalized technologies and the resulting patient empowerment. Roger raises questions around the commercial model buttressing this study: who is paying and for how long can they maintain motivation? He envisions a more viable approach will be supported by commercial payers, who in return are investing in health care data. Given this may take some time to play out, Roger casts a third suggestion: FDA-approved digital therapeutic apps. He predicts this to be fertile grounds for patient empowerment over the next few years. After some back and forth with Jeff, Roger shifts focus to his interest in posters on primary care screening and the metabolic-NAFLD link. Mazen shares his enthusiasm for the potential of machine learning to ensure accuracy in the use of NITs.As time winds down, the panelists provide closing comments touching on a number of topics. It's noted that this data-rich, insight-laden conference will host a dynamic inclusion of presentations on therapeutics, drug development and solutions deployed to market. Stay tuned for the upcoming live recorded coverage from Washington DC.

Host: Denise M. Dupras, M.D., Ph.D. Guest: Andres J. Acosta, M.D., Ph.D. (@dr_aac) The obesity epidemic continues to escalate in the United States and obesity rates are increasing around the world. It is estimated that by 2030, 50% of adults and 25% of children worldwide will be obese. Patients are the interaction of their genetics and environment; this episode explores the importance of understanding the mechanisms behind food intake regulation and weight to develop individualized therapies to treat obesity. Our guest for this episode is Andres J. Acosta, M.D., Ph.D., a physician-scientist at Mayo Clinic in Rochester, Minnesota. He is also an assistant professor of medicine at Mayo Clinic College of Medicine and Science, and principal investigator of the Precision Medicine for Obesity Laboratory.

While licking his waffle ice cream cone, Chairman Joe claims the economy is "strong as hell". The GOP plans for the FBI & Biden crime family.  The Dem crime wave is turning voters to the GOP. The Pelosi Trump rap battle and MAGA Republicans perform well in their debates.Copyright Sean Casey All Rights Reserved

Our week of "Greatest Hits" episodes from the vault continues with our most popular conversation ever, as Stephen Harrison and Jörn Schattenberg synopsize the Basic Science segment of the recent Paris NASH meeting. This segment, which focuses largely on a state-of-the-art look at fibrosis, is by far our most downloaded conversation every, with more volume than the next four posts combined!As I wrote at the time: Paris NASH is a meeting for basic science and interdisciplinary thinking. Since Stephen Harrison was drafted into co-chairing the session titled "Deep Dive into Fibrosis," he led this conversation. The session included three presentations with a powerful collective message about stellate cells: that different stellate cell subtypes perform in unique ways in terms of how they function, the process(es) through which they become modified and what this represents in terms of performance. This description does not do Stephen and Jörn's comments justice. It's a short session, so listen for yourself...

Medical instruments that are 3D printed could help astronauts analyze medical samples in space.

 Dr. Tommy Sors, Assistant Director of the Purdue Institute of Inflammation, Immunology and Infectious Disease (PI4D), explains the role that STEM professionals in all fields play in sequencing genes to understand the instructions for life found in every cell. This field of study is known as genomics, but within this field, there are many other “-omics.” How about the field of study involving RNA copied from DNA made within the cell? Transcriptomics. The field of instructions on how to make proteins? Proteomics. The study of proteins metabolizing within the cell? Metabolomics. Each of these fields creates a flood of information that requires computational science to help scientists better understand the data.

David Brady, ND, DC, CCN, DACBN, IFMCP, FACN, MS, DC, joins Integrative Practitioner associate editor, Avery St. Onge, to discuss the benefits of using omics (i.e., microbiomics, genomics, metabolomics, etc.) testing in a clinical practice to help personalize the treatment of patients with mental health issues. This episode is sponsored by Diagnostic Solutions Laboratory. Find us at integrativepractitioner.com or e-mail us at IPEditor@divcom.com. Theme music: “Upbeat Party” by Scott Holmes via freemusicarchive.org and “Carefree” by Kevin Mcleod via incompetech.com.

Today we are addressing questions that our listeners have asked! You ask; we answer! As stated in the previous episode, the concepts included  in omics (fields of study in biological sciences that end with “omics,” such as genomics, proteomics, and others) and how much these fields can impact health are valuable. With the new science information that is available, medicine has expanded its scope to personalize medicines, diet, and exercise to benefit you as you age. Tune in today for an in-depth conversation to learn how research has developed to help you age better.